http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
S-340 : A case of successful RFA for bilateral RCC in VHL
( Sang Yi Moon ),( Dong Hyun Kim ),( Eui Han Jung ),( So Young Park ),( Mi Kyung Park ),( Duk Kyu Kim ),( Sung Hwan Suh ) 대한내과학회 2013 대한내과학회 추계학술대회 Vol.2013 No.1
Von Hippel-Lindau (VHL) disease is an inherited, autosomal dominant syndrome manifested by a variety of benign and malignant tumors in various organs. Especially, renal cell carcinomas (RCC) in patients with VHL disease tends to be multifocal, bilateral, and recur or develop new tumors after removal. Recently, Radiofrequency ablation (RFA) has been introduced as a minimally-invasive treatment for small hereditary RCCs associated with a low complication rate and a minimal decrease in renal function. We present a case of successful RFA of multiple bilateral RCCs in a 24-year-old woman with VHL. The patient came to our clinic due to intermittent palpitation and tingling sensation in both hand and foot. Hypertension with elevated 24hr Urine Vanillylmandelic acid and metanephrine were observed. Computed Tomography (CT) of abdomen revealed multiple, bilateral RCCs and bilateral pheochromocytomas. The subsequent gene testing showed a germline mutation in exon 1 codon 80 of the VHL gene. After bilateral adrenalectomy of pheochromocytomas, the patient received sequential RFA for bilateral RCCs resulting in complete response. Until now, there is no sign of any recurrence or renal failure. In conclusion, Percutaneous RFA is a promising treatment for VHL patients who cannot undergo surgery because of excellent treatment outcome and minimal change of renal function.
Morphological and Molecular Classifications of Genus Pholis
Sung-Hoon Lee,장요순,Chung-Boo Baik,Kyeong-Ho Han,Jung-Goo Myung,Jin-Hee Lee,Sang-Duk Choi,Seon-Jae Kim,김종오,황재호 한국통합생물학회 2009 Animal cells and systems Vol.13 No.4
Morphological and molecular classifications were attempted in an effort to establish species-specific classifications of three species of the genus Pholis in Korea; these species were subjected to morphological and molecular methodologies using body measurements, RFLP, RAPD, and phylogenetic trees using the nucleotide sequences of mitochondrial 16S and 12S ribosomal DNAs, cytochrome c oxidase I, and cytochrome b. The data demonstrated that the three species of genus Pholis are distinct from each other, both morphologically and genetically.
( Sang Yeob Lee ),( Yong Jun Kim ),( Sang Hyeon Kang ),( Dong Yeol Lee ),( Duk Song Cho ),( Kyong Han Kim ),( Won Tae Chung ),( Sung Won Lee ) 대한내과학회 2011 대한내과학회 추계학술대회 Vol.2011 No.1
The NSAIDs and celecoxib in the treatment of rheumatoid arthritis and osteoarthritis had been used for a long time.However, in vitro animal model, these drugs had been reported that inhibit PGE2 and suppressed the PGE2 production by osteoblasts is involved in the mechanism of bone resorption recently. so the influence of NSAIDs and celecoxib on the patient`s actual bone density was studied. We enrolled 445 patients (Rheumatoid arthritis 256, Osteoarthritis 189), and investigated an use of NSAIDs effects on bone mineral density. All patients included in the study of the patients receiving bisphosphonate. To evaluation of bone mineral density, the Hologic QDR dual energy x ray absorptiometry was regularly performed at intervals of one year, but one-year intervals to observe changes in bone mineral density thought to be too short observation period, two-year trend of change in bone mineral density measured. The NSAIDs administered in each of the patients and the NSAIDs have adverse effects on patients were treated on behalf of celecoxib. Both patients with rheumatoid arthritis, the average steroid prednisolone 10 mg / day was in use, the NSAIDs of the 140 people, the celecoxib was used the 116 patients. The patients with osteoarthritis did not use steroids, NSAIDs was used 106 patients, celecoxib was used 83 patients. In patients with rheumatoid arthritis, the average disease duration of 8 years, the average age is 70 years old and received treatment with NSAIDs or celecoxib period was an average of 4 years, in patients with degenerative arthritis, 7.8 years, 69 years old, was 3 years. During the observation period of the average change of the T-score showed increased in both groups. Patients with rheumatoid arthritis, lumbar portion of 0.11, hip portion 0.01, and patients with degenerative arthritis, lumbar portion 0.15, hip portion 0.06, were increased. Statistically in the groups with the administration of NSAIDs or celecoxib on bone mineral density did not affect. However, The use of bisposphonate was significant (p<0.05). In conclusion, the treatment of NSAIDs or celecoxib did not affect bone mineral density in rheumatoid arthritis patients or patients with degenerative arthritis.
Discussion of Critical Design Review (CDR) for MIRIS, the Main Payload of STSAT-3
Han, Won-Yong,Lee, Dae-Hee,Nam, Uk-Won,Park, Young-Sik,Jeong, Woong-Seob,Ree, Chang-Hee,Moon, Bong-Kon,Park, Sung-Joon,Cha, Sang-Mok,Park, Jang-Hyun,Lee, Duk-Hang,Ka, Nung-Hyun,Lee, Mi-Hyun,Seon, Kwan 한국우주과학회 2009 한국우주과학회보 Vol.18 No.2
( Duk Han Kim ),( Hyun Jong Lee ),( Chun Wook Park ),( Kyu Han Kim ),( Kwang Hoon Lee ),( Byung In Ro ),( Sang Hyun Cho ) 대한피부과학회 2013 Annals of Dermatology Vol.25 No.1
Background: Topical application of corticosteroids also has an influence on skin barrier impairment. Physiological lipid mixtures, such as multi- lamellar emulsion (MLE) containing a natural lipid component leads to effective recovery of the barrier function. Objective: The purpose of this study was to conduct an evaluation of the therapeutic efficacy and skin barrier protection of topical mometasone furoate in MLE. Methods: A multi-center randomized, double-blind, controlled study was performed to assess the efficacy and safety of mometasone furoate cream in MLE for Korean patients with eczema. The study group included 175 patients with eczema, who applied either mometasone furoate in MLE cream or methylprednisolone aceponate cream for 2 weeks. Treatment efficacy was evaluated using the physician`s global assessment of clinical response (PGA), trans-epidermal water loss (TEWL), and visual analogue scale (VAS) for pruritus. Patients were evaluated using these indices at days 4, 8, and 15. Results: Comparison of PGA score, TEWL, and VAS score at baseline with those at days 4, 8, and 15 of treatment showed a significant improvement in both groups. Patients who applied mometasone furoate in MLE (74.8%) showed better results (p<0.05) than those who applied methylprednisolone aceponate (47.8%). The TEWL improvement ratio was higher in the mometasone furoate in MLE group than that in the methylprednisolone aceponate group, and VAS improvement was also better in the mometasone furoate in MLE group. Conclusion: Mometasone furoate in MLE has a better therapeutic efficacy as well as less skin barrier impairment than methylprednisolone aceponate. (Ann Dermatol 25(1) 17∼22, 2013)